NDAORALTABLET
Approved
Jul 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
BACTRIM DS (sulfamethoxazole and trimethoprim) by PharmaIN is dihydrofolate reductase inhibitors [moa]. First approved in 1973.
Drug data last refreshed 3h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BACTRIM DS is a fixed-dose combination of sulfamethoxazole and trimethoprim, oral antibiotics indicated for bacterial infections including urinary tract infections, Pneumocystis jirovecii pneumonia (PCP) prophylaxis, and other susceptible gram-positive and gram-negative infections. The combination works synergistically by inhibiting dihydrofolate reductase, blocking folic acid synthesis in susceptible organisms. This dual mechanism provides enhanced bactericidal activity and reduces resistance development.
$0.019BPart D
LOE ApproachingStable
As an established generic-competing product approaching LOE, the brand team is likely small and focused on maintenance rather than growth, with limited expansion opportunities.
Mechanism of Action
Dihydrofolate Reductase Inhibitors
Pharmacologic Class:
Dihydrofolate Reductase Inhibitor Antibacterial
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on BACTRIM DS offers limited career growth due to its mature LOE-approaching lifecycle and minimal linked job opportunities (0 current openings). Career value lies primarily in managing a stable, legacy product and defending market share against generics rather than driving innovation or launching new therapeutic areas.
Brand Manager
Worked on BACTRIM DS at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.